$19.52
7.94% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$19.63
+1.45 7.98% 1M
-5.91 23.14% 6M
-6.07 23.62% YTD
-20.69 51.31% 1Y
+8.63 78.45% 3Y
+12.08 160.00% 5Y
+8.44 75.42% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.55 8.57%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $1.72b
Enterprise Value $1.05b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 150.38
P/S ratio (TTM) P/S ratio 245.60
P/B ratio (TTM) P/B ratio 1.68
Revenue growth (TTM) Revenue growth -54.85%
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-360.35m
Free Cash Flow (TTM) Free Cash Flow $-267.98m
Cash position $692.51m
EPS (TTM) EPS $-3.59
P/E forward negative
P/S forward 117.42
EV/Sales forward 71.90
Short interest 14.66%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
92%
Hold
8%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7 7
55% 55%
100%
- Direct Costs 3.89 3.89
5% 5%
56%
3.12 3.12
73% 73%
45%
- Selling and Administrative Expenses 37 37
67% 67%
526%
- Research and Development Expense 323 323
123% 123%
4,611%
-356 -356
130% 130%
-5,092%
- Depreciation and Amortization 3.89 3.89
5% 5%
56%
EBIT (Operating Income) EBIT -360 -360
126% 126%
-5,148%
Net Profit -307 -307
138% 138%
-4,387%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
Seeking Alpha
6 days ago
Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of darovasertib as a neoadjuvant for uveal melanoma, starting in the first half of 2025. IDE849 is an ADC targeting DLL3 in SCLC and NETs, This program has two catalysts: phase 1 data in Q3 2025 and a...
Neutral
PRNewsWire
15 days ago
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filing Successful FDA Type D meeting ...
Neutral
PRNewsWire
15 days ago
Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability Targeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025 SOUTH SAN FRANCISCO, Calif. , May 6, 2025 /PRNewswire/ -- IDEAYA Biosci...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today